Targeting the population for gene therapy with MYBPC3

Area of Science:

• Cardiology
• Genetics
• Molecular Biology

Background:

• Hypertrophic cardiomyopathy (HCM) is the most common inherited heart muscle disease.
• It is characterized by unexplained thickening of the left ventricle, leading to diastolic dysfunction and potential arrhythmias or sudden death.
• Mutations in sarcomere protein genes, particularly MYBPC3, are frequent causes of HCM.

Purpose of the Study:

• To investigate the role of MYBPC3 mutations in hypertrophic cardiomyopathy.
• To identify patient subgroups with severe phenotypes who could benefit from novel therapies.
• To propose MYBPC3 gene therapy as a potential treatment for specific HCM patient populations.

Main Methods:

• Analysis of MYBPC3 gene mutations in patients with hypertrophic cardiomyopathy.
• Assessment of clinical phenotypes associated with different mutation types (single, double heterozygous, compound heterozygous, homozygous).
• Review of existing therapeutic approaches and their impact on prognosis.

Main Results:

• MYBPC3 is the most frequently mutated gene in HCM, with truncating mutations being common.
• Pathogenic MYBPC3 variants lead to undetectable cardiac myosin-binding protein C in affected heart tissue.
• Patients with multiple MYBPC3 mutations (double heterozygous, compound heterozygous, homozygous) exhibit more severe clinical presentations compared to single heterozygotes.

Conclusions:

• MYBPC3 mutations are a major genetic driver of hypertrophic cardiomyopathy.
• Individuals with multiple MYBPC3 mutations represent a distinct, more severely affected patient group.
• These patients are ideal candidates for developing and testing MYBPC3-targeted gene therapies for HCM.